Jonathan Trent, MD, PhD

Sylvester Comprehensive Cancer Center, University of Miami Health System

Poster(s):

• (P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB

• (P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA

• (P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE

• (P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS

• (P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES

• (P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY

• (P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER

• (P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY

• (P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA

• (P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL

• (P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY

• (P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE